Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31761566.
- Also identified by DOI 10.1016/j.cmet.2019.10.014 and PMC identifier 7028360.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oxidized phospholipids (OxPLs), which arise due to oxidative stress, are proinflammatory and proatherogenic, but their roles in non-alcoholic steatohepatitis (NASH) are unknown. Here, we show that OxPLs accumulate in human and mouse NASH. Using a transgenic mouse that expresses a functional single-chain variable fragment of E06, a natural antibody that neutralizes OxPLs, we demonstrate the causal role of OxPLs in NASH. Targeting OxPLs in hyperlipidemic Ldlr-/- mice improved multiple aspects of NASH, including steatosis, inflammation, fibrosis, hepatocyte death, and progression to hepatocellular carcinoma. Mechanistically, we found that OxPLs promote ROS accumulation to induce mitochondrial dysfunction in hepatocytes. Neutralizing OxPLs in AMLN-diet-fed Ldlr-/- mice reduced oxidative stress, improved hepatic and adipose-tissue mitochondrial function, and fatty-acid oxidation. These results suggest targeting OxPLs may be an effective therapeutic strategy for NASH.
Medical subject headings
- Apoptosis
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Mitochondria
- Non-alcoholic Fatty Liver Disease
- Oxidative Stress
- Phospholipids
- Single-Chain Antibodies